MDXG Revises Q3 Outlook, Two Down, One To Go For BLPH, TECH Opens Wallet

Today's Daily Dose brings you news about Atara's orphan drug status for its drug candidate ATA230; Bellerophon's positive top line data from phase II trial of INOpulse; BioCryst's encouraging phase II hereditary angioedema trial results and Bio-Techne's acquisition of Trevigen.

from RTT - Biotech http://ift.tt/2xNFRDk
via IFTTT